Jane Street Group LLC Makes New $309,000 Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Jane Street Group LLC bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,151 shares of the company’s stock, valued at approximately $309,000.

Other large investors also recently bought and sold shares of the company. Wellington Management Group LLP acquired a new stake in Bicara Therapeutics during the third quarter worth about $19,458,000. Soros Fund Management LLC bought a new stake in Bicara Therapeutics in the third quarter valued at $509,000. Samsara BioCapital LLC bought a new position in shares of Bicara Therapeutics during the third quarter worth about $891,000. RA Capital Management L.P. bought a new position in shares of Bicara Therapeutics during the third quarter worth about $177,169,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $1,420,000.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on BCAX shares. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price for the company. HC Wainwright started coverage on Bicara Therapeutics in a research report on Friday, December 6th. They set a “buy” rating and a $42.00 price objective for the company. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price on the stock. RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Finally, TD Cowen assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics currently has an average rating of “Buy” and a consensus target price of $43.00.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $15.25 on Friday. Bicara Therapeutics Inc. has a 1-year low of $15.15 and a 1-year high of $28.09. The business’s 50 day moving average price is $19.64.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.